Bernstein SocGen Group increased its price target for Eli Lilly to $1,385 from $1,300.
The firm maintains an Outperform rating on the pharmaceutical company.
Analysts expect Eli Lilly to exceed earnings expectations and raise its guidance.
The stock climbed 30% during the second quarter.
Shares currently trade near their 52-week high.
Guggenheim and Truist Securities also recently adjusted their price targets upward.
Bernstein noted mixed factors may impact the company in 2026.
The launch of the oral obesity drug Foundayo is under scrutiny after a weak start.